Ruijian Pharmaceuticals Receives NMPA IND Approval for NouvNeu003, a Novel iPSC-Derived Cell Therapy Targeting Early-Onset Parkinson’s Disease

36Kr learned that on December 11, the National Medical Products Administration (NMPA) officially approved the IND application for iRegene's pipeline NouvNeu003. This pipeline targets early-onset Parkinson's disease, addressing Parkinson's patients under the age of 50. Following the approval in August this year for the company’s Parkinson's drug NouvNeu001 to conduct a “combined Phase I-II clinical trial,” this marks the second IND approval received by iRegene within the year.